Article thumbnail

Treatment of DIO mice with either FGF19 or FGF21 improves metabolic dysfunction.

By Andrew C. Adams (297152), Tamer Coskun (297154), Armando R. Irizarry Rovira (320850), Michael A. Schneider (320851), David W. Raches (320852), Radmila Micanovic (320853), Holly A. Bina (320854), James D. Dunbar (320855) and Alexei Kharitonenkov (297155)


<p>Administration of recombinant FGF19 or FGF21 led to a reduction in body mass in a dose dependent fashion (A). Both FGF19 and FGF21 therapy led to a trend towards increased food intake, however, these differences were not significant (B). Treatment with FGF19 or FGF21 significantly reduced adiposity at both doses tested again in a dose dependant manner (C), All FGF treatments caused a significant reduction in serum glucose in DIO animals, furthermore, the reduction in glucose observed with the two proteins was strikingly similar (D).</p

Topics: Physiology, Chemistry, dio, mice, fgf19, fgf21, improves, metabolic
Year: 2013
DOI identifier: 10.1371/journal.pone.0038438.g005
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.